[go: up one dir, main page]

PL3761035T3 - Test do określania potencjału samoasocjacji białka za pomocą spektroskopii zależnych od stężenia samoodziaływań nanocząstek - Google Patents

Test do określania potencjału samoasocjacji białka za pomocą spektroskopii zależnych od stężenia samoodziaływań nanocząstek

Info

Publication number
PL3761035T3
PL3761035T3 PL20191942.0T PL20191942T PL3761035T3 PL 3761035 T3 PL3761035 T3 PL 3761035T3 PL 20191942 T PL20191942 T PL 20191942T PL 3761035 T3 PL3761035 T3 PL 3761035T3
Authority
PL
Poland
Prior art keywords
self
assay
protein
association
concentration
Prior art date
Application number
PL20191942.0T
Other languages
English (en)
Inventor
Michael Marlow
Michael Sennett
Michael Schneider
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of PL3761035T3 publication Critical patent/PL3761035T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587Nanoparticles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845Methods of identifying protein-protein interactions in protein mixtures
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N2021/258Surface plasmon spectroscopy, e.g. micro- or nanoparticles in suspension

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
PL20191942.0T 2016-08-18 2017-08-18 Test do określania potencjału samoasocjacji białka za pomocą spektroskopii zależnych od stężenia samoodziaływań nanocząstek PL3761035T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662376788P 2016-08-18 2016-08-18

Publications (1)

Publication Number Publication Date
PL3761035T3 true PL3761035T3 (pl) 2024-06-24

Family

ID=59746357

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20191942.0T PL3761035T3 (pl) 2016-08-18 2017-08-18 Test do określania potencjału samoasocjacji białka za pomocą spektroskopii zależnych od stężenia samoodziaływań nanocząstek
PL17761159T PL3500856T3 (pl) 2016-08-18 2017-08-18 Oznaczenie umożliwiające określenie potencjału białka do samoasocjacji za pomocą spektroskopii zależnych od stężenia samoodziaływań nanocząstek (CD-SINS)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17761159T PL3500856T3 (pl) 2016-08-18 2017-08-18 Oznaczenie umożliwiające określenie potencjału białka do samoasocjacji za pomocą spektroskopii zależnych od stężenia samoodziaływań nanocząstek (CD-SINS)

Country Status (19)

Country Link
US (3) US11428695B2 (pl)
EP (2) EP3761035B1 (pl)
JP (3) JP6959327B2 (pl)
KR (3) KR102534506B1 (pl)
CN (2) CN109661577B (pl)
AU (2) AU2017313150B2 (pl)
BR (1) BR112019003175A2 (pl)
CA (1) CA3032361A1 (pl)
DK (2) DK3500856T3 (pl)
EA (1) EA201990316A1 (pl)
ES (2) ES2974961T3 (pl)
FI (1) FI3761035T3 (pl)
HU (2) HUE052805T2 (pl)
IL (2) IL307435A (pl)
MX (2) MX2019001930A (pl)
PL (2) PL3761035T3 (pl)
SG (1) SG11201900895QA (pl)
WO (1) WO2018035470A1 (pl)
ZA (1) ZA201901035B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102534506B1 (ko) 2016-08-18 2023-05-30 리제너론 파마슈티칼스 인코포레이티드 농도-의존적 자가-상호작용 나노입자 분광법을 사용하는 단백질의 자가-결합하는 능력을 결정하기 위한 분석
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度vegf受容体融合タンパク質を含む製剤
CN113588582B (zh) * 2020-04-30 2024-05-14 上海药明生物技术有限公司 蛋白质样品浓度测定方式选择法及测定方法
WO2023095154A1 (en) * 2021-11-24 2023-06-01 Sensoville Biotech Pvt Ltd Method for determining changes in a protein's structure
WO2023141319A1 (en) * 2022-01-24 2023-07-27 Amgen Inc. Methods for detecting antibody self-association

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US771997A (en) 1903-11-21 1904-10-11 Alfred Palm Lathe attachment.
US4254102A (en) * 1975-09-08 1981-03-03 Plough, Inc. Substantive PABA compositions
US4080264A (en) 1976-03-01 1978-03-21 Massachusetts Institute Of Technology Immunoassay by light scattering spectroscopy
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7514938B2 (en) 2004-05-11 2009-04-07 Board Of Regents Of The University And College System Of Nevada, On Behalf Of The University Of Nevada, Reno Dielectric relaxation spectroscopy apparatus and methods of use
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
WO2007121363A2 (en) 2006-04-13 2007-10-25 Mississippi State University An optical apparatus for simultaneously measuring the scattering and concentration signals of macromolecules in a flow cell
CN101522219A (zh) 2006-10-12 2009-09-02 惠氏公司 改变抗体溶液中离子强度以减少乳光/聚集物
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2009039502A1 (en) * 2007-09-21 2009-03-26 Cytimmune Sciences, Inc. Nanotherapeutic colloidal metal compositions and methods
WO2010059963A2 (en) 2008-11-21 2010-05-27 The Board Of Regents Of The University Of Texas System Preparation and methodology of silk fibroin nanoparticles
EP2993460B1 (en) 2013-05-30 2019-07-03 Osaka Prefecture University Public Corporation Target-substance detection apparatus and method
IL312865B1 (en) * 2013-09-11 2025-02-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
US20160074515A1 (en) * 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
CN104062287B (zh) 2014-07-01 2017-08-08 福建工程学院 一种基于纳米金催化的化学发光分析检测铁蛋白的方法
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
WO2016115475A1 (en) * 2015-01-18 2016-07-21 Biogen Ma Inc. Anti-cd40 antibody formulations
KR102534506B1 (ko) 2016-08-18 2023-05-30 리제너론 파마슈티칼스 인코포레이티드 농도-의존적 자가-상호작용 나노입자 분광법을 사용하는 단백질의 자가-결합하는 능력을 결정하기 위한 분석

Also Published As

Publication number Publication date
US20190187149A1 (en) 2019-06-20
EP3761035A1 (en) 2021-01-06
BR112019003175A2 (pt) 2019-06-18
US11988668B2 (en) 2024-05-21
EA201990316A1 (ru) 2019-07-31
ES2974961T3 (es) 2024-07-02
JP7321227B2 (ja) 2023-08-04
AU2017313150A1 (en) 2019-02-21
US11428695B2 (en) 2022-08-30
KR20190039185A (ko) 2019-04-10
JP2023139189A (ja) 2023-10-03
KR102534506B1 (ko) 2023-05-30
IL264640B1 (en) 2023-11-01
EP3500856A1 (en) 2019-06-26
EP3500856B1 (en) 2020-10-07
IL264640B2 (en) 2024-03-01
JP6959327B2 (ja) 2021-11-02
JP2022008959A (ja) 2022-01-14
MX2019001930A (es) 2019-07-04
KR102717462B1 (ko) 2024-10-16
US20220357335A1 (en) 2022-11-10
CN115468919A (zh) 2022-12-13
HUE052805T2 (hu) 2021-05-28
JP2019532267A (ja) 2019-11-07
US20240280582A1 (en) 2024-08-22
DK3761035T3 (da) 2024-03-11
CN109661577A (zh) 2019-04-19
IL307435A (en) 2023-12-01
DK3500856T3 (da) 2020-12-14
KR102441221B1 (ko) 2022-09-07
AU2017313150B2 (en) 2023-09-14
KR20220126801A (ko) 2022-09-16
CN109661577B (zh) 2022-09-27
FI3761035T3 (fi) 2024-03-18
CA3032361A1 (en) 2018-02-22
AU2023274236A1 (en) 2023-12-21
PL3500856T3 (pl) 2021-04-19
SG11201900895QA (en) 2019-02-27
HUE066064T2 (hu) 2024-07-28
ZA201901035B (en) 2024-06-26
KR20230074614A (ko) 2023-05-30
WO2018035470A1 (en) 2018-02-22
WO2018035470A9 (en) 2018-07-05
EP3761035B1 (en) 2024-02-14
IL264640A (pl) 2019-04-30
ES2837093T3 (es) 2021-06-29
MX2023013583A (es) 2023-11-30

Similar Documents

Publication Publication Date Title
HUE066064T2 (hu) Fehérje önasszociációs képességének meghatározására szolgáló assay koncentrációfüggõ öninterakciós nanorészecske-spektroszkópia segítségével
IL294490A (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3283882A4 (en) BLOOD-BASED BIOMARKERS OF TUMOR SENSITIVITY AGAINST PD-1 ANTAGONISTS
DK3317658T3 (da) Turbiditetssensor baseret på ultralydsmålinger
CL2014003140A1 (es) Anticuerpos aislado que se une a ly6e; metodo de produccion; inmunoconjugado que lo contiene; formulacion farmaceutica que lo contiene y métodos de uso.
BR112018005175A2 (pt) predição de resposta clínica a antagonistas de il23 usando biomarcadores de via de il23
EP2833894A4 (en) MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF COSMETIC PROTEINS AND PEPTIDES
HUE055465T2 (hu) PD-L1 ellenes humán antitestek
EP3102102A4 (en) Integrated analysis of electrophysiological data
EP3112870A4 (en) Sensor chip for surface plasmon-field enhanced fluorescence spectroscopy
IL249395A0 (en) Quantitative analysis of transgenic proteins
EP2892548A4 (en) COMBINATIONS OF MODALITIES FOR THE TREATMENT OF DIABETES
EP3204008A4 (en) Use of biomarkers for predicting clinical sensitivity to cancer treatment
EP3340796A4 (en) PROBES OF HUNTINGTIN PROTEIN IMAGINATION
IL250949B (en) Biosensors based on g-beta-gamma reactive proteins for monitoring g-protein activation
HK1255839A1 (zh) 與人crth2特異性結合的抗體
EP3154583A4 (en) Human monoclonal antibodies to ganglioside gd2
GB201507530D0 (en) Computer-implemented methods of website analysis
MA41048A (fr) Utilité d'une protéine dans la prédiction d'effets in vivo
EP3542310A4 (en) DETECTION OF FINGERPRINTS USING MEASUREMENT CONFIGURATIONS WITH DIFFERENT MAIN EXTENSION DIRECTIONS
HK1244444A1 (zh) 檢測人dpp-4的測定法
EP2748334A4 (en) PROTEIN INVOLVED IN THE DETECTION OF CANCER MEASURES AND TREATMENT THEREOF
GB201402689D0 (en) Ratiometric low-field analyser for consumption analysis
TH1601001388A (th) สารเพื่อลดแคแทบอลิซึมหรือกระตุ้นแอนาบอลิซึมของโปรตีน
IL249880A0 (en) A method for developing recombinant proteins with a fingerprint similar to a relative product